febit Receives US Patent for Microfluidic Extraction Method

febit Expands its Leading Position in Next-Generation Sequencing
(PresseBox) (Lexington, Mass. (USA), and Heidelberg, Germany, ) febit today announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA.

This method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system Geniom® for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.

febit microfluidic biochip systems have been successfully used for several years in DNA analysis and synthesis. The latest patent was now granted in the US, patents in Europe and other foreign countries will soon follow.

febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents. Using a focussed application strategy, febit has been able to secure intellectual property rights on important product components, processes and evolving technologies.

Kontakt

Hummingbird Diagnostics GmbH
Im Neuenheimer Feld 519
D-69120 Heidelberg
Eva Sterzel
febit holding gmbh
Presse- und Öffentlichkeitsarbeit
David Schull
Russo Partners , LLC
Wendy Lau
Russo Partners , LLC
Social Media